JP6602746B2 - 非ペプチジル結合を含むハイブリッド免疫グロブリン - Google Patents

非ペプチジル結合を含むハイブリッド免疫グロブリン

Info

Publication number
JP6602746B2
JP6602746B2 JP2016503119A JP2016503119A JP6602746B2 JP 6602746 B2 JP6602746 B2 JP 6602746B2 JP 2016503119 A JP2016503119 A JP 2016503119A JP 2016503119 A JP2016503119 A JP 2016503119A JP 6602746 B2 JP6602746 B2 JP 6602746B2
Authority
JP
Japan
Prior art keywords
fab
peg
compound according
amino acids
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016503119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520529A (ja
JP2016520529A5 (enExample
Inventor
カポン、ダニエル・ジェイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016520529A publication Critical patent/JP2016520529A/ja
Publication of JP2016520529A5 publication Critical patent/JP2016520529A5/ja
Priority to JP2019185908A priority Critical patent/JP6987401B2/ja
Application granted granted Critical
Publication of JP6602746B2 publication Critical patent/JP6602746B2/ja
Priority to JP2021190174A priority patent/JP7489111B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2016503119A 2013-03-15 2014-03-14 非ペプチジル結合を含むハイブリッド免疫グロブリン Active JP6602746B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019185908A JP6987401B2 (ja) 2013-03-15 2019-10-09 非ペプチジル結合を含むハイブリッド免疫グロブリン
JP2021190174A JP7489111B2 (ja) 2013-03-15 2021-11-24 非ペプチジル結合を含むハイブリッド免疫グロブリン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799784P 2013-03-15 2013-03-15
US61/799,784 2013-03-15
PCT/US2014/029511 WO2014144911A2 (en) 2013-03-15 2014-03-14 Hybrid immunoglobulin containing non-peptidyl linkage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019185908A Division JP6987401B2 (ja) 2013-03-15 2019-10-09 非ペプチジル結合を含むハイブリッド免疫グロブリン

Publications (3)

Publication Number Publication Date
JP2016520529A JP2016520529A (ja) 2016-07-14
JP2016520529A5 JP2016520529A5 (enExample) 2017-04-20
JP6602746B2 true JP6602746B2 (ja) 2019-11-06

Family

ID=51538392

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503119A Active JP6602746B2 (ja) 2013-03-15 2014-03-14 非ペプチジル結合を含むハイブリッド免疫グロブリン
JP2019185908A Active JP6987401B2 (ja) 2013-03-15 2019-10-09 非ペプチジル結合を含むハイブリッド免疫グロブリン
JP2021190174A Active JP7489111B2 (ja) 2013-03-15 2021-11-24 非ペプチジル結合を含むハイブリッド免疫グロブリン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019185908A Active JP6987401B2 (ja) 2013-03-15 2019-10-09 非ペプチジル結合を含むハイブリッド免疫グロブリン
JP2021190174A Active JP7489111B2 (ja) 2013-03-15 2021-11-24 非ペプチジル結合を含むハイブリッド免疫グロブリン

Country Status (8)

Country Link
US (2) US11220556B2 (enExample)
EP (3) EP4039281A1 (enExample)
JP (3) JP6602746B2 (enExample)
CA (1) CA2906175C (enExample)
DK (2) DK3611180T3 (enExample)
ES (1) ES2759061T3 (enExample)
PT (1) PT3611180T (enExample)
WO (1) WO2014144911A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022043050A (ja) * 2013-03-15 2022-03-15 バイオモレキュラー・ホールディングス・エルエルシー 非ペプチジル結合を含むハイブリッド免疫グロブリン

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6231263B2 (ja) 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
ES2932285T3 (es) 2014-03-14 2023-01-17 Biomolecular Holdings Llc Compuestos útiles en la preparación de inmunoglobulina híbrida que contiene una unión distinta de peptidilo
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
DK4001303T3 (da) * 2019-07-18 2025-08-04 Hanmi Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af langtidsvirkende lægemiddelkonjugat ved fremstilling af et nyt mellemprodukt
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
US20230220116A1 (en) * 2022-01-12 2023-07-13 Biomolecular Holdings Llc Tetrahedral antibodies
US20250084169A1 (en) 2022-01-12 2025-03-13 Biomolecular Holdings Llc Nk/monocyte engagers

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5169770A (en) 1987-12-21 1992-12-08 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
ES2038579T3 (es) 1989-04-28 1997-02-16 Rhein Biotech Proz & Prod Gmbh Celulas de levadura del genero schwanniomyces.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5536637A (en) 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US5838464A (en) 1995-11-02 1998-11-17 Eastman Kodak Company System and method for scanning images contained on a strip of photosensitive film
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US20030077654A1 (en) 1997-09-17 2003-04-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
PL209786B1 (pl) * 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897285B2 (en) 2002-02-28 2005-05-24 New England Biolabs, Inc. Modified chitin binding domain and uses thereof
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2766627C (en) * 2003-05-02 2019-12-03 Xencor, Inc. Optimized fc variants and methods for their generation
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
US20050186208A1 (en) 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
CA2568952C (en) * 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007048127A2 (en) 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
DK3284825T3 (da) 2006-11-02 2021-05-25 Biomolecular Holdings Llc Fremgangsmåder til at fremstille hybride polypeptider med bevægelige dele
PL2352521T3 (pl) * 2008-10-14 2021-03-08 Genentech, Inc. Warianty immunoglobuliny i ich zastosowania
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
EP2400992B1 (en) * 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
US10434197B2 (en) 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
HK1198173A1 (en) * 2011-03-16 2015-03-13 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
MX364707B (es) 2011-05-08 2019-05-06 Legochem Biosciences Inc Conjugados de proteina-agente activo y método para su preparación.
CN103732256A (zh) 2011-05-16 2014-04-16 皇家飞利浦有限公司 生物正交药物活化
US10081684B2 (en) * 2011-06-28 2018-09-25 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
BR112014002219A2 (pt) 2011-07-05 2018-08-07 Bioasis Technologies Inc conjugados anticorpo p97 e métodos de sua utilização
EP2784080B1 (en) 2011-10-31 2019-12-18 Shimadzu Corporation Peptide-hinge-free flexible antibody-like molecule
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
JP6231263B2 (ja) 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
PT2943548T (pt) * 2013-01-14 2023-02-22 Roquette Freres Utilização de uma combinação de amido de leguminosa/amido de tubérculo para reduzir o teor de boro numa composição adesiva, e composições adesivas que compreendem uma tal combinação
JP6602746B2 (ja) 2013-03-15 2019-11-06 カポン、ダニエル・ジェイ． 非ペプチジル結合を含むハイブリッド免疫グロブリン
ES2932285T3 (es) * 2014-03-14 2023-01-17 Biomolecular Holdings Llc Compuestos útiles en la preparación de inmunoglobulina híbrida que contiene una unión distinta de peptidilo
JP7042144B2 (ja) * 2018-04-04 2022-03-25 日産自動車株式会社 電極活物質スラリーの製造方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022043050A (ja) * 2013-03-15 2022-03-15 バイオモレキュラー・ホールディングス・エルエルシー 非ペプチジル結合を含むハイブリッド免疫グロブリン
JP7489111B2 (ja) 2013-03-15 2024-05-23 バイオモレキュラー・ホールディングス・エルエルシー 非ペプチジル結合を含むハイブリッド免疫グロブリン

Also Published As

Publication number Publication date
US11220556B2 (en) 2022-01-11
EP2968495A2 (en) 2016-01-20
CA2906175C (en) 2022-12-13
EP3611180A1 (en) 2020-02-19
US20160024226A1 (en) 2016-01-28
JP2016520529A (ja) 2016-07-14
HK1220623A1 (en) 2017-05-12
JP2022043050A (ja) 2022-03-15
EP2968495B1 (en) 2019-07-03
JP2020033358A (ja) 2020-03-05
JP6987401B2 (ja) 2022-01-05
DK3611180T3 (da) 2022-02-28
DK2968495T3 (da) 2019-10-14
PT3611180T (pt) 2022-03-15
WO2014144911A3 (en) 2014-12-04
CA2906175A1 (en) 2014-09-18
WO2014144911A2 (en) 2014-09-18
JP7489111B2 (ja) 2024-05-23
ES2759061T3 (es) 2020-05-07
EP4039281A1 (en) 2022-08-10
US20220275108A1 (en) 2022-09-01
EP2968495A4 (en) 2016-11-09
EP3611180B1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
JP7475690B2 (ja) 非ペプチジル結合を含むハイブリッド免疫グロブリン
JP7489111B2 (ja) 非ペプチジル結合を含むハイブリッド免疫グロブリン
WO2022011358A9 (en) Tetrahedral antibodies
WO2023137373A1 (en) Tetrahedral antibodies
US12509502B2 (en) Hybrid immunoglobulin containing nonpeptidyl linkage
HK40024252A (en) Hybrid immunoglobulin containing non-peptidyl linkage
HK40024252B (en) Hybrid immunoglobulin containing non-peptidyl linkage
HK40093101A (en) Process for preparing hybrid immunoglobulin containing non-peptidyl linkage
HK40037262A (en) Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage
HK40037262B (en) Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage
HK1220623B (en) Hybrid immunoglobulin containing non-peptidyl linkage
HK1234647B (en) Hybrid immunoglobulin containing non-peptidyl linkage
HK1234647A1 (en) Hybrid immunoglobulin containing non-peptidyl linkage

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191009

R150 Certificate of patent or registration of utility model

Ref document number: 6602746

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250